Evidence map›Paper›PMID 36103814›Full record

ArticleCell reports2022

Pak2-mediated phosphorylation promotes RORγt ubiquitination and inhibits colonic inflammation.

Mahesh Kathania, Ritesh Kumar, Elviche Taskem Lenou, Venkatesha Basrur, Arianne L Theiss, Jonathan Chernoff, K Venuprasad

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Mahesh KathaniaDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Immunology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Ritesh KumarDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Immunology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Elviche Taskem LenouDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Immunology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Venkatesha BasrurDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Arianne L TheissUniversity of Colorado, School of Medicine, Division of Gastroenterology and Hepatology, Anschutz Medical Campus, Aurora, CO, USA.
Jonathan ChernoffCancer Signaling and Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
K VenuprasadDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Immunology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: venuprasad.poojary@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USFox Chase Cancer Center · USSouthwestern Medical CenterUniversity of Colorado Anschutz Medical Campus · USUniversity of Michigan–Ann Arbor · US

Funding

UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeff G McDonald · 2022 to 2026
$7.4M
Regulation of CD8+T cells by Zbtb42R01CA266072 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Venuprasad K Poojary · 2022 to 2026
$2.1M
Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunityR01AI155786 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI POOJARY, VENUPRASAD K · 2021 to 2025
$2.1M
Mitochondrial Dysfunction and Mitophagy in IleitisR01DK117001 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI THEISS, ARIANNE L · 2018 to 2022
$1.9M
Regulation of ROR-gt in colonic inflammationR01DK115668 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI POOJARY, VENUPRASAD K · 2018 to 2021
$1.5M
NCI NIH HHS R01 CA266072NIAID NIH HHS R01 AI155786NIDDK NIH HHS P30 DK127984NIDDK NIH HHS R01 DK115668NIDDK NIH HHS R01 DK117001
6 · The paper itself

Abstract

Dysregulated interleukin-17 (IL-17) expression and its downstream signaling is strongly linked to inflammatory bowel diseases (IBDs). However, the molecular mechanisms by which the function of RORγt, the transcription factor of IL-17, is regulated remains elusive. By a mass spectrometry-based approach, we identify that Pak2, a serine (S)/threonine (T) kinase, directly associates with RORγt. Pak2 recognizes a conserved KRLS motif within RORγt and phosphorylates the S-316 within this motif. Genetic deletion of Pak2 in Th17 cells reduces RORγt phosphorylation, increases IL-17 expression, and induces severe colitis upon adoptive transfer to Rag1

Indexed as

ColitisNuclear Receptor Subfamily 1, Group F, Member 3AnimalsInflammationInterleukin-17Micep21-Activated KinasesPhosphorylationUbiquitinationInterleukin-17Nuclear Receptor Subfamily 1, Group F, Member 3p21-Activated KinasesPak2 protein, mouseCP: Immunologyinterleukin-17Pak2posttranslational modificationRORγtulcerative colitis

Identifiers

PMID36103814
PMCPMC9510046
OpenAlexW4295900658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.